The trailing P/E of 0.59 is driven by a reported earnings base that swings sharply between quarters, so it likely overstates the discount rather than signaling clear undervaluation. The forward EV/EBITDA of 10.69 sits closer to the peer range, which implies that enterprise value rather than equity value may be the more reliable anchor. Investors should monitor whether the gap between the near-zero equity multiples and the enterprise-level multiple persists, since it reflects the heavy debt load sitting ahead of common shareholders.

The gross margin series is distorted by cost classification shifts, including a reading of negative 134.6% in 2025Q4, so gross margin is unlikely to be a dependable profitability gauge here. Operating margin across the 2025 quarters averages roughly in the high single digits, which may be a more defensible measure of recurring earnings. Net margin remains negative in several periods, suggesting non-operating items are material and warrant further investigation before treating any single quarter as representative.

Return on equity is not meaningful given the stockholders' deficit, so ROIC is the more relevant capital efficiency measure here. The sub-4% range implies that the capital base, which includes roughly $3.2B of goodwill, is earning returns below typical cost of capital for leveraged hospital operators. Investors should monitor whether margin recovery lifts ROIC or whether the capital base continues to absorb returns without improvement.

Coverage near 1x leaves little margin for error if operating income softens, and the reported debt-to-EBITDA readings suggest debt is large relative to the earnings base. Total debt of roughly $10.2B against a negative equity position implies that creditors, rather than shareholders, hold the economic claim on most of the enterprise. Investors should monitor refinancing timelines and whether coverage improves toward sustainable levels, as the current structure may warrant further investigation into refinancing exposure.